ROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS

Objective: To determine the role of Rosuvastatin as a possible treatment of sudden sensorineural hearing loss. Study Design: Quasi-experimental study. Place and Duration of Study: ENT Departments, Combined Military Hospital Quetta & Combined Military Hospital Lahore, from Apr 2015 to Sep 2...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nadeem Ul Haq, Zeeshan Ayub Sheikh, Ahmed Hasan Ashfaq, Azeema Ahmed, Naeema Ahmed
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2019
Materias:	hyperlipidemias rosuvastatin Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2dca5ccce2b24d82b408903c6f988399
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2dca5ccce2b24d82b408903c6f988399
record_format	dspace
spelling	oai:doaj.org-article:2dca5ccce2b24d82b408903c6f9883992021-11-05T04:16:22ZROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS0030-96482411-8842https://doaj.org/article/2dca5ccce2b24d82b408903c6f9883992019-12-01T00:00:00Zhttps://www.pafmj.org/index.php/PAFMJ/article/view/3630/2453https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To determine the role of Rosuvastatin as a possible treatment of sudden sensorineural hearing loss. Study Design: Quasi-experimental study. Place and Duration of Study: ENT Departments, Combined Military Hospital Quetta & Combined Military Hospital Lahore, from Apr 2015 to Sep 2017. Methodology: This quasi-experimental study performed at Combined Military Hospital Quetta & Combined Military Hospital Lahore comprised of seventy-eight patients of sudden sensorineural hearing loss (SSNHL) having hyperlipidemia. Patients pre-treatment total serum cholesterol was measured, and hearing loss in speech frequencies was recorded on audiometry. The seventy-eight patients were administered tablet Rosuvastatin 10mg once daily with low fat diet for 4 months. On completion of 4 months of treatment, patients were selected by using non probability purposive sampling and divided into responder and non-responder group depending on total serum cholesterol levels. Post treatment total serum cholesterol levels and improvement in hearing levels were also recorded and graded according to siegel’s criteria. Results: Total serum cholesterol came to within normal limits in 43 (55.1%) patients (responder), while it remained high in 35 (44.9%) patients (non-responder group). Improvement in hearing scores was assessed using siegel’s criteria. pearson chi square test showed statistically significant improvement (p=0.001) in hearing scores among responder group as compared to non-responder group. Conclusion: Sudden sensorineural hearing loss, in patients having hyperlipidemia, can be managed by treating hyperlipidemia with lipidlowering agent rosuvastatin.Nadeem Ul HaqZeeshan Ayub SheikhAhmed Hasan AshfaqAzeema AhmedNaeema AhmedArmy Medical College RawalpindiarticlehyperlipidemiasrosuvastatinMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 69, Iss 6, Pp 1184-1188 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	hyperlipidemias rosuvastatin Medicine R Medicine (General) R5-920
spellingShingle	hyperlipidemias rosuvastatin Medicine R Medicine (General) R5-920 Nadeem Ul Haq Zeeshan Ayub Sheikh Ahmed Hasan Ashfaq Azeema Ahmed Naeema Ahmed ROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS
description	Objective: To determine the role of Rosuvastatin as a possible treatment of sudden sensorineural hearing loss. Study Design: Quasi-experimental study. Place and Duration of Study: ENT Departments, Combined Military Hospital Quetta & Combined Military Hospital Lahore, from Apr 2015 to Sep 2017. Methodology: This quasi-experimental study performed at Combined Military Hospital Quetta & Combined Military Hospital Lahore comprised of seventy-eight patients of sudden sensorineural hearing loss (SSNHL) having hyperlipidemia. Patients pre-treatment total serum cholesterol was measured, and hearing loss in speech frequencies was recorded on audiometry. The seventy-eight patients were administered tablet Rosuvastatin 10mg once daily with low fat diet for 4 months. On completion of 4 months of treatment, patients were selected by using non probability purposive sampling and divided into responder and non-responder group depending on total serum cholesterol levels. Post treatment total serum cholesterol levels and improvement in hearing levels were also recorded and graded according to siegel’s criteria. Results: Total serum cholesterol came to within normal limits in 43 (55.1%) patients (responder), while it remained high in 35 (44.9%) patients (non-responder group). Improvement in hearing scores was assessed using siegel’s criteria. pearson chi square test showed statistically significant improvement (p=0.001) in hearing scores among responder group as compared to non-responder group. Conclusion: Sudden sensorineural hearing loss, in patients having hyperlipidemia, can be managed by treating hyperlipidemia with lipidlowering agent rosuvastatin.
format	article
author	Nadeem Ul Haq Zeeshan Ayub Sheikh Ahmed Hasan Ashfaq Azeema Ahmed Naeema Ahmed
author_facet	Nadeem Ul Haq Zeeshan Ayub Sheikh Ahmed Hasan Ashfaq Azeema Ahmed Naeema Ahmed
author_sort	Nadeem Ul Haq
title	ROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS
title_short	ROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS
title_full	ROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS
title_fullStr	ROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS
title_full_unstemmed	ROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS
title_sort	rosuvastatin as a possible treatment for sudden sensorineural hearing loss
publisher	Army Medical College Rawalpindi
publishDate	2019
url	https://doaj.org/article/2dca5ccce2b24d82b408903c6f988399
work_keys_str_mv	AT nadeemulhaq rosuvastatinasapossibletreatmentforsuddensensorineuralhearingloss AT zeeshanayubsheikh rosuvastatinasapossibletreatmentforsuddensensorineuralhearingloss AT ahmedhasanashfaq rosuvastatinasapossibletreatmentforsuddensensorineuralhearingloss AT azeemaahmed rosuvastatinasapossibletreatmentforsuddensensorineuralhearingloss AT naeemaahmed rosuvastatinasapossibletreatmentforsuddensensorineuralhearingloss
_version_	1718444519769243648

ROSUVASTATIN AS A POSSIBLE TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS

Ejemplares similares